Quellen

Gastmeier P et al. 2016. Nosokomiale Infektionen und Infektionen mit multiresistenten Erregern – Häufigkeit und Sterblichkeit. Dtsch Med Wochenschr 2016;141(6):421–426
Cassine et al. 2019. Attributable deaths and disability-adjusted life years caused by infections with antibiotic-resistantbacteria in the EU and the European Economic Area in 2015: a population-level modellinganalysis. Lancet Infect Dis. 2019 Jan;19(1):56-66
https://www.aerztezeitung.de/medizin/krankheiten/infektionskrankheiten/mre/article/975405/33000-tote-jaehrlich-immer-todesfaelle-wegen-antibiotika-resistenzen.html (abgerufen am 10.07.2019)
Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. January 2016. Available at: http://amr-review.org/sites/default/files/Tackling%20drug-resistant%20infections%20-%20An%20overview%20of%20our%20work_LR_NOCROPS.pdf
Bush K. The ABCD’s of β-lactamase nomenclature. J Infect Chemother 2013;19(4):549–559
Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 2015;46(5):483–493
Nordmann P. Emerging antibiotic resistance in Gram-negati- ves. ICAAC 2015, Antimicrobial Research Award and Lectures
Navarro-San Francisco C. An ESBL-colonized patient with signs of infection in an emergency room. ECCMID 2016, Amsterdam NL, E083
Shorr A. Setting the stage – Gram-negative resistance in the ICU: epidemiology, outcomes, and strategies. Emerging options for complicated Gram-negative infections: considerations for intra-abdominal and urinary tract infections. CME Lunch Symposium. IDWeek 2018, San Francisco, CA
Sahm D, Biedenbach D, Hackel M et al. Characterization and profiling of multi-drug resistant (MDR) Enterobacteriaceae from Italy during five surveillance years (TEST program).
Biedenbach D, Hackel M, Leister-Tebbe H et al. Trends in susceptibility of Gram-negative ESKAPE pathogens in hospitalized patients in the United States (US) compared to Europe (EU). 25th ECCMID, Kopenhagen, DK, April 25–28, 2015, EV0225
Garcie C, Robin F, Malavaud S et al. Spread of DHA-1 producing Klebsiella pneumoniae isolates in ICUs and emergency units at Toulouse University Hospital, France, 2010-2013. 25th ECCMID, Kopenhagen, DK, April 25–28, 2015, P1050
Lübbert C, Becker-Rux D, Rodloff AC et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 2014;42(2):309–316
Tabah A, Koulenti D, Laupland K et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT Internatio- nal Cohort Study. Intensive Care Med 2012;38(12):1930– 1945
Maechler F, Peňa Diaz LA, Schröder C et al. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection 2015;43(2):163–168
Maechler F, Peňa Diaz LA, Schröder C et al. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection 2015;43(2):163–168
Maragakis LL. Recognition and prevention of multidrug-re- sistant Gram-negative bacteria in the intensive care unit. Crit Care Med 2010;38(8 Suppl):S345–351
Micek ST, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015;19:219.
de Kraker ME, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66:398–407.
Schwaber M, Klarfeld-Lidji S. Predictors of carbapenem-resistant acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents. Chemother 2008;52:1028–33.
Kaye KS, Pogue JM. Infections caused by resistant gram- negative bacteria: epidemiology and management. Pharmacotherapy 2015;35(10):949–962.
Tacconelli E, Cataldo MA, Dancer SJ et al. ESCMID guideli- nes for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014;20 Suppl 1:1–55
Fussen R, Lemmen S. Multiresistente Erreger auf der Intensi- vstation: Sinnvolle Maßnahmen zur Prävention. Med Klin Intensivmed Notfmed 2016;111(8):743–754
Vincent JA et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009;302:2323-2329
https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (abgerufen am 10.07.2019)
Zilberberg MD et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care Med 2014;18:596

Zurück zur Übersicht

Bakterielle Infektionen mit multiresistenten gramnegativen Erregern

Pfizerpro bietet als Service- und Informationsportal für den medizinischen Fachkreis wissenschaftliche Inhalte, CME zertifizierte Fortbildungen sowie Service für Fachkreise und deren Patient:innen.

Sie verlassen jetzt PfizerPro.de

Sie verlassen jetzt eine von Pfizer betriebene Webseite. Die Links zu allen externen Webseiten werden als Information für unsere Besucher bereitgestellt. Pfizer übernimmt keine Verantwortung für den Inhalt von Webseiten, die nicht zu Pfizer gehören und nicht von Pfizer betrieben werden.